Efficacy and Safety of Daratumumab in the Treatment of Relapsed/Refractory Multiple Myeloma: a Meta-Analysis of Randomized Controlled Trials
s conducted using electronic databases (PubMed, Web of Science, Embase, and Cochrane Central Register of Controlled Trials databases) up to December 2022. We conducted a meta-analysis of randomized controlled trials...
Our results suggest that daratumumab-based regimens are effective in the treatment of RRMM, improving progression-free survival, minimal residual disease, and overall response rate. However, there is an increased risk of pneumonia, upper respiratory tract infections, and diarrhea. Further studies are needed to determine the long-term safety...
BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma - Annals of Hematology
Source : https://link.springer.com/article/10.1007/s00277-023-05444-7
Recently, many new therapies have improved the outcomes of patients with relapsed and/or refractory multiple myeloma (RRMM). Nevertheless, recurrence is still unavoidable, and better treatment choices for RRMM are urgently...
Relevance: In this review, we focus on data from RRMM patients involved in clinical trials of Ide-cel and Cilta-cel and discuss the present situation and future direction of CAR T cell therapy for this condition.
Management of Adverse Reactions for BCMA-Directed Therapy in Relapsed Multiple Myeloma: A Focused Review
Source : https://www.mdpi.com/2077-0383/12/17/5539
Anti-B-cell maturation antigen therapies consisting of bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor T cells have shown promising results in relapsed refractory multiple myeloma (RRMM). However, the severe side...
Conclusions: MM is the second most common hematologic malignancy, which remains incurable despite advances in its treatment secondary to drug resistance and the presence of minimal residual disease. Recently, BCMA agents have shown favorable outcomes in heavily pre-treated RRMM cohorts, as evidenced by multiple published clinical trials....
Post-infusion Costs Associated with Idecabtagene Vicleucel Treatment for Patients with Relapsed/Refractory Multiple Myeloma in the KarMMa Trial - Advances in Therapy
Source : https://link.springer.com/article/10.1007/s12325-023-02623-w
Introduction Patients with triple-class exposed relapsed/refractory multiple myeloma (RRMM) have poor outcomes with substantial healthcare costs. Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell...
Conclusions: Extrapolation of costs based on HCRU data from patients receiving single-infusion of ide-cel in the KarMMa trial showed substantially reduced HCRU and costs over 2 years after initial treatment. Most costs were incurred during the first month after ide-cel infusion, likely attributable to the 14-day inpatient stay required by the...
"Waitlist mortality" is high for myeloma patients with limited access to BCMA therapy
Source : https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1206715/full
BackgroundThe first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel (ide-cel), approved in March 2021, for RRMM patients who progressed after 4 or more lines of therapy. Despite the promising outcomes,...
Conclusion(s): Many patients who were eligible for ide-cel were not able to secure a timely slot in 2021. Mortality was higher in this group, due to a lack of comparable alternatives. Increasing alternate options as well as improvement in manufacturing and access is an area of high importance to improve RRMM outcomes.